RxDoctor Payments DataLook up a doctor →

Carrie Dougherty, MD

Neurology · Washington, DCNPI 1326294430

Payments from drug & device makers

$429,787in general payments, 2019–2025

Across 891 payments — averaging $482.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$109K
  • Pfizer$85K
  • Lilly USA, LLC$72K
  • Teva Pharmaceuticals USA, Inc.$52K
  • Amgen$50K
  • Eli Lilly$19K
  • plus $43K from 34 others
$13,749in research payments, 2019–2025

Across 2 payments — averaging $6874.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$13K
  • Amgen$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$429,787 in reported general payments places this provider in the 85th percentile of 113 neurology providers in District of Columbia.

See all neurology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$324,853
Medicare patients
128
Services billed
40,444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →